Heiko Hermeking

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 17

Top Topics

Gene Expression

Top Venues

Cancer communications (London, England)

Cell death and differentiation

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Jinjiang Chou, Markus Kaller, Matjaz Rokavec, Fangteng Liu, Heiko Hermeking
AP4 induces JNK1 and a miR-22-3p/FOSL1 feed-forward loop to activate AP-1 and promote colorectal cancer metastasis. Cancer communications (London, England) 44 (3) (2024)
Jinjiang Chou, Markus Kaller, Matjaz Rokavec, Fangteng Liu, Heiko Hermeking
AP4 induces JNK1 and a miR-22-3p/FOSL1 feed-forward loop to activate AP-1 and promote colorectal cancer metastasis. Cancer communications (London, England) (2024)
Jinjiang Chou, Markus Kaller, Matjaz Rokavec, Fangteng Liu, Heiko Hermeking
AP4 induces JNK1 and a miR-22-3p/FOSL1 feed-forward loop to activate AP-1 and promote colorectal cancer metastasis. Cancer communications (London, England) (2024)
Markus Kaller, Ignasi Forne, Axel Imhof, Heiko Hermeking
LINC01021 Attenuates Expression and Affects Alternative Splicing of a Subset of p53-Regulated Genes. Cancers 16 (9) (2024)
Markus Kaller, Ignasi Forne, Axel Imhof, Heiko Hermeking
LINC01021 Attenuates Expression and Affects Alternative Splicing of a Subset of p53-Regulated Genes. Cancers 16 (9) (2024)
Jinjiang Chou, Markus Kaller, Matjaz Rokavec, Fangteng Liu, Heiko Hermeking
AP4 induces JNK1 and a miR-22-3p/FOSL1 feed-forward loop to activate AP-1 and promote colorectal cancer metastasis. Cancer communications (London, England) 44 (3) (2024)
Jinjiang Chou, Markus Kaller, Matjaz Rokavec, Fangteng Liu, Heiko Hermeking
AP4 induces JNK1 and a miR-22-3p/FOSL1 feed-forward loop to activate AP-1 and promote colorectal cancer metastasis. Cancer communications (London, England) 44 (3) (2024)
Chunfeng Liu, Matjaz Rokavec, Zekai Huang, Heiko Hermeking
Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis. Cell death & disease 14 (10) (2023)
Markus Kaller, Wenjing Shi, Heiko Hermeking
c-MYC-Induced AP4 Attenuates DREAM-Mediated Repression by p53. Cancers 15 (4) (2023)
Chunfeng Liu, Matjaz Rokavec, Zekai Huang, Heiko Hermeking
Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis. Cell death and differentiation (2023)
Matjaz Rokavec, Elif Özcan, Jens Neumann, Heiko Hermeking
Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer. Cancer research communications 3 (8) (2023)
Markus Kaller, Wenjing Shi, Heiko Hermeking
c-MYC-Induced AP4 Attenuates DREAM-Mediated Repression by p53. Cancers 15 (4) (2023)
Matjaz Rokavec, Stephanie Jaeckel, Heiko Hermeking
Nidogen-1/NID1 Function and Regulation during Progression and Metastasis of Colorectal Cancer. Cancers 15 (22) (2023)
Markus Kaller, Wenjing Shi, Heiko Hermeking
c-MYC-Induced AP4 Attenuates DREAM-Mediated Repression by p53. Cancers 15 (4) (2023)
Zekai Huang, Markus Kaller, Heiko Hermeking
CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells: comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34. Cell death and differentiation (2023)
Leon P Loevenich, Markus Tschurtschenthaler, Matjaz Rokavec, Miguel G Silva, Moritz Jesinghaus, Thomas Kirchner, Frederick Klauschen, Dieter Saur, Jens Neumann, Heiko Hermeking, Peter Jung
SMAD4 loss induces c-MYC-mediated NLE1 upregulation to support protein biosynthesis, colorectal cancer growth and metastasis. Cancer research (2022)
Anna-Katharina Wirth, Lucas Wange, Sebastian Vosberg, Kai-Oliver Henrich, Christian Rausch, Erbey Özdemir, Christina M Zeller, Daniel Richter, Tobias Feuchtinger, Markus Kaller, Heiko Hermeking, Philipp A Greif, Daniela Senft, Vindi Jurinovic, Ehsan Bahrami, Ashok Kumar Jayavelu, Frank Westermann, Matthias Mann, Wolfgang Enard, Tobias Herold, Irmela Jeremias
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance. Leukemia 36 (12) (2022)